Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 10/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 4/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAP2 | P11137 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21956760 | 0.84 | KDM5A (0.52) | KDM5AKDM5BPARP1CSNK2A1KDM5C | |
| SCHEMBL22017182 | 0.78 | PARP1 (0.50) | KDM5AKDM5BPARP1KDM5CKIF11 | |
| SCHEMBL13708891 | 0.71 | PARP1 (0.55) | KDM5AKDM5BPARP1CSNK2A1KDM5C | |
| SCHEMBL25430812 | 0.70 | KDM5A (0.57) | KDM5AKDM5BPARP1CSNK2A1KDM5C | |
| SCHEMBL13818061 | 0.70 | KDM5A (0.72) | KDM5AKDM5BPARP1KDM5CPADI4 | |
| SCHEMBL13708855 | 0.70 | PARP1 (0.54) | KDM5AKDM5BPARP1CSNK2A1KDM4E | |
| SCHEMBL31139842 | 0.70 | KDM5A (0.57) | KDM5AKDM5BPARP1CSNK2A1KDM5C | |
| SCHEMBL31423272 | 0.69 | MEN1 (0.39) | PARP1KDM4ETDP1 | |
| SCHEMBL31146052 | 0.68 | PARP1 (0.42) | KDM5APARP1CSNK2A1KIF11KDM4C | |
| SCHEMBL30744743 | 0.68 | PARP1 (0.52) | KDM5AKDM5BPARP1CSNK2A1KDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM5B 1244/4885PARP1 1100/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM5B 1244/4885PARP1 1100/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | KDM5A 2656/4885KDM5B 903/4885PARP1 1472/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDM5A 2386/4885KDM5B 1244/4885PARP1 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.